JP3228512B2 - Ｃ型肝炎を治療する組成物および方法 - Google Patents

Ｃ型肝炎を治療する組成物および方法

Info

Publication number
JP3228512B2
JP3228512B2 JP50608393A JP50608393A JP3228512B2 JP 3228512 B2 JP3228512 B2 JP 3228512B2 JP 50608393 A JP50608393 A JP 50608393A JP 50608393 A JP50608393 A JP 50608393A JP 3228512 B2 JP3228512 B2 JP 3228512B2
Authority
JP
Japan
Prior art keywords
thymosin
interferon
patients
hepatitis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP50608393A
Other languages
English (en)
Japanese (ja)
Other versions
JPH06510998A (ja
Inventor
クレティーン，ポール
マッチニック，ミルトン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wayne State University
Sciclone Pharmaceuticals LLC
Original Assignee
Wayne State University
Sciclone Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne State University, Sciclone Pharmaceuticals LLC filed Critical Wayne State University
Publication of JPH06510998A publication Critical patent/JPH06510998A/ja
Application granted granted Critical
Publication of JP3228512B2 publication Critical patent/JP3228512B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Beans For Foods Or Fodder (AREA)
JP50608393A 1991-09-13 1992-09-08 Ｃ型肝炎を治療する組成物および方法 Expired - Fee Related JP3228512B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75954491A 1991-09-13 1991-09-13
US759,544 1991-09-13
PCT/US1992/007556 WO1993005806A1 (en) 1991-09-13 1992-09-08 Composition and method of treating hepatitis c

Publications (2)

Publication Number Publication Date
JPH06510998A JPH06510998A (ja) 1994-12-08
JP3228512B2 true JP3228512B2 (ja) 2001-11-12

Family

ID=25056052

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50608393A Expired - Fee Related JP3228512B2 (ja) 1991-09-13 1992-09-08 Ｃ型肝炎を治療する組成物および方法

Country Status (23)

Country Link
US (3) US6001799A (enExample)
EP (1) EP0603305B1 (enExample)
JP (1) JP3228512B2 (enExample)
KR (1) KR100254082B1 (enExample)
AT (1) ATE152914T1 (enExample)
AU (1) AU667327B2 (enExample)
CA (1) CA2119006C (enExample)
CZ (1) CZ286827B6 (enExample)
DE (1) DE69219782T2 (enExample)
DK (1) DK0603305T3 (enExample)
ES (1) ES2103966T3 (enExample)
FI (1) FI107879B (enExample)
GR (1) GR3024025T3 (enExample)
HK (1) HK1021687A1 (enExample)
HU (1) HU221006B1 (enExample)
MX (1) MX9205240A (enExample)
NO (1) NO941310L (enExample)
RO (1) RO111991B1 (enExample)
RU (1) RU2104010C1 (enExample)
SG (1) SG64897A1 (enExample)
TW (1) TW224053B (enExample)
WO (1) WO1993005806A1 (enExample)
ZA (1) ZA926964B (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224053B (enExample) * 1991-09-13 1994-05-21 Paul B Chretien
SG64892A1 (en) * 1992-02-06 1999-05-25 Sciclone Pharmaceuticals Method for treating hepatitis b carriers with minimal disease
EP0627930A4 (en) * 1992-07-13 1997-08-20 Kenneth E Sherman COMPOSITION AND METHOD FOR TREATING HEPATITIS B.
AU751199B2 (en) * 1992-07-13 2002-08-08 Government Of The United States Of America As Represented By The Secretary Of The Army Composition and method of treating hepatitis B
CN1072961C (zh) * 1993-03-05 2001-10-17 施塞克龙药品公司 治疗对干扰素治疗无反应者的丙型肝炎的方法
US6200952B1 (en) * 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
TW249754B (enExample) * 1993-10-26 1995-06-21 Alpha I Biomedicals Inc
ES2194860T3 (es) * 1993-11-05 2003-12-01 Sciclone Pharmaceuticals Inc Composiciones que contienen timosina alfa 1 destinadas al tratamiento de pacientes que sufren una enfermedad hepatica descompensada.
JP3837769B2 (ja) * 1995-06-12 2006-10-25 大塚製薬株式会社 抗ウイルス剤
JP2000506839A (ja) * 1996-02-28 2000-06-06 アイエフアイ ノスチチュート ファルマコテラピコ イタリアーノ ソシエタ ペル アチオニ 天然ヒトα―インターフェロンを含む薬剤組成物
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
IL153020A0 (en) 2000-05-26 2003-06-24 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
EA007785B1 (ru) * 2000-08-07 2007-02-27 Сайклоун Фармасьютикалз, Инк. Способ лечения гепатита с с помощью тимозина, интерферона и рибавирина
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
US6878364B2 (en) * 2000-12-01 2005-04-12 Cornell Research Foundation, Inc. Animal model for flaviviridae infection
RU2211703C2 (ru) * 2001-06-08 2003-09-10 ООО НТЦ "Юпитер-2" Антистрессорное и ноотропное средство с антивирусным и иммуностимулирующим действием
JP2005504087A (ja) * 2001-09-28 2005-02-10 イデニクス（ケイマン）リミテツド ４’が修飾されたヌクレオシドを使用するｃ型肝炎ウイルス治療のための方法および組成物
HUP0600449A2 (en) * 2001-10-05 2006-09-28 Intermune Methods of treating liver fibrosis and hepatitis c virus infection
PL370453A1 (en) * 2001-10-26 2005-05-30 Rhode Island Hospital Thymosin augmentation of genetic immunization
UA80957C2 (en) * 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
WO2003068162A2 (en) * 2002-02-14 2003-08-21 Pharmasset Ltd. Modified fluorinated nucleoside analogues
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
CN1678326A (zh) 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
EP1523489B1 (en) 2002-06-28 2014-03-12 IDENIX Pharmaceuticals, Inc. Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
KR20050088079A (ko) 2002-11-15 2005-09-01 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이
MXPA05006230A (es) 2002-12-12 2005-09-20 Idenix Cayman Ltd Proceso para la produccion de nucleosidos ramificados-2'.
GB0301879D0 (en) * 2003-01-27 2003-02-26 Regent Res Llp HCV combination therapy
JP4149296B2 (ja) * 2003-03-26 2008-09-10 株式会社ルネサステクノロジ 半導体記憶装置
KR101089145B1 (ko) 2003-03-28 2011-12-02 사이클론 파아머슈티컬 인코오퍼레이티드 티모신 알파 1에 의한 아스퍼르길러스 감염의 치료 의약품
DE602004027127D1 (de) * 2003-03-28 2010-06-24 Sciclone Pharmaceuticals Inc Behandlung von aspergillus-infektionen mit thymosin alpha 1
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
ES2906207T3 (es) 2003-05-30 2022-04-13 Gilead Pharmasset Llc Análogos de nucleósidos fluorados modificados
JP2007501185A (ja) 2003-07-25 2007-01-25 イデニクス（ケイマン）リミテツド Ｃ型肝炎を含むフラビウイルス関連疾患を治療するためのプリンヌクレオシド類似体
WO2005021007A1 (fr) * 2003-08-28 2005-03-10 Obschestvo S Ogranichennoi Otvetstvennostju 'berezovy Mir' Prevention et traitement de l'hepatite virale b
KR20070011451A (ko) 2004-05-05 2007-01-24 예일 유니버시티 신규의 항바이러스 헬리오크산틴 유사체
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
JP5001842B2 (ja) 2004-09-14 2012-08-15 ギリアド ファーマセット エルエルシー ２’−フルオロ−２’−アルキル−置換又は他の置換されていてもよいリボフラノシルピリミジン類及びプリン類並びにそれらの誘導体の製造
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
JP5254033B2 (ja) 2005-12-23 2013-08-07 イデニク プハルマセウティカルス，インコーポレイテッド 分岐型ヌクレオシドを調製するための合成中間体の製造方法
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
CA2649063C (en) * 2006-05-02 2014-11-25 Luigina Romani Use of thymosin .alpha.1, alone or in combination with ptx3 or ganciclovir, for the treatment of cytomegalovirus infection
ES2288118B1 (es) * 2006-05-10 2008-11-01 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US20110195048A1 (en) * 2008-10-08 2011-08-11 Podack Eckhard R Regulation of lymphocytes and uses therefor
EP2376515A1 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Synthesis of purine nucleosides
NZ593648A (en) 2008-12-23 2013-09-27 Gilead Pharmasset Llc Nucleoside phosphoramidates
BRPI0922508A8 (pt) 2008-12-23 2016-01-19 Pharmasset Inc Análogos de nucleosídeo
JP2012526149A (ja) 2009-05-08 2012-10-25 サイクローン・ファーマシューティカルズ・インコーポレイテッド ワクチン増強剤としてのαチモシンペプチド
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
CN102858790A (zh) 2010-03-31 2013-01-02 吉利德制药有限责任公司 核苷氨基磷酸酯
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
CN103800293B (zh) * 2012-11-09 2015-10-21 长春海悦药业有限公司 一种含有胸腺法新的药物组合物及其制剂
US20150064253A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Combination formulation of two antiviral compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1216056B (it) * 1988-03-11 1990-02-22 Sclavo Spa Composizioni farmaceutiche contenenti timosina alfa 1.
US5273963A (en) * 1991-03-29 1993-12-28 The George Washington University Compositions and methods for treating small cell and nonsmall cell lung cancers
TW224053B (enExample) * 1991-09-13 1994-05-21 Paul B Chretien

Also Published As

Publication number Publication date
RO111991B1 (ro) 1997-04-30
HU221006B1 (hu) 2002-07-29
HU9400758D0 (en) 1994-06-28
US20070218033A1 (en) 2007-09-20
DE69219782D1 (de) 1997-06-19
HUT75166A (en) 1997-04-28
ES2103966T3 (es) 1997-10-01
CA2119006C (en) 2005-08-23
US6001799A (en) 1999-12-14
ZA926964B (en) 1993-04-26
RU94022480A (ru) 1996-07-20
CZ286827B6 (cs) 2000-07-12
CA2119006A1 (en) 1993-04-01
AU667327B2 (en) 1996-03-21
WO1993005806A1 (en) 1993-04-01
RU2104010C1 (ru) 1998-02-10
AU2644792A (en) 1993-04-27
TW224053B (enExample) 1994-05-21
DE69219782T2 (de) 1997-10-09
EP0603305B1 (en) 1997-05-14
FI941133L (fi) 1994-03-10
US5849696A (en) 1998-12-15
NO941310D0 (no) 1994-04-12
KR100254082B1 (ko) 2000-09-01
FI941133A0 (fi) 1994-03-10
MX9205240A (es) 1993-07-01
CZ55194A3 (en) 1994-10-19
JPH06510998A (ja) 1994-12-08
SG64897A1 (en) 1999-05-25
HK1021687A1 (en) 2000-06-23
GR3024025T3 (en) 1997-10-31
DK0603305T3 (da) 1997-09-01
FI107879B (fi) 2001-10-31
EP0603305A1 (en) 1994-06-29
ATE152914T1 (de) 1997-05-15
NO941310L (no) 1994-04-12

Similar Documents

Publication Publication Date Title
JP3228512B2 (ja) Ｃ型肝炎を治療する組成物および方法
HK1021687B (en) Use of a thymosin in the treatment of hepatitis c
Björkander et al. Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency
CA2236591C (en) Continuous low-dose cytokine infusion therapy
Lok et al. Interferon antibodies may negate the antiviral effects of recombinant α-interferon treatment in patients with chronic hepatitis B virus infection
Douglas et al. Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C: comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM
WO1994001125A1 (en) Composition and method of treating hepatitis b
EP0687181B1 (en) Use of thymosin for treating hepatitis c in non-responders to interferon treatment
Mauser‐Bunschoten et al. Effect and side‐effects of alpha interferon treatment in haemophilia patients with chronic hepatitis C
JPH07258109A (ja) Ｃ型肝炎の処置法および処置用組成物
Mutchnick et al. Thymosin: An innovative approach to the treatment of chronic hepatitis B
AU751199B2 (en) Composition and method of treating hepatitis B
JPH072693A (ja) 肝炎処置用医薬組成物

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080907

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090907

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100907

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110907

Year of fee payment: 10

LAPS Cancellation because of no payment of annual fees